INCY: INCYTE CORP Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

U.S. Markets open in 8 hrs, 26 mins

Symbol	Value	Change	Percentage Change
DJIA	11,430.21	12.78	0.11%
NASDAQ	2,380.38	-8.70	-0.36%
S&P 500	1,277.72	3.18	0.25%

INCYTE CORP

INCY

Stock price

9.54 -0.25 -2.55%

as of 04:00 PM EDT on 08/21/2008 in USD (NASDAQ Delay: 15 mins.)
Extended Hours

9.539 -0.001 -0.01%

as of 04:27 PM EDT on 08/21/08

Analyst Consensus

Buy
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts

INCYTE CORP Profile

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

Paul A. Friedman, M.D.: CEO

Experimental Station, Route 141 & Henry Clay Road, Bldg. E33

Wilmington, DE 19880

http://www.incyte.com

Phone: 302-498-6700

Fax: 302-425-2750

Sector: Healthcare Industry: Drugs

2007 Sales	2007 Sales Growth	2007 Net Income	Employees
$34,400,000	24.6%	$-86,900,000

Key Executives: INCY

Name	Title	Officer Since
Paul A. Friedman, M.D.	CEO	11/1/01
David C. Hastings, CPA	CFO	-
Patricia A. Schreck	General Counsel	-
Brian W. Metcalf, Ph.D.	Executive VP	-
John A. Keller, Ph.D.	Executive VP	-
Richard U. De Schutter	Chairman of the Board/Director	1/1/01
Paul A. Brooke	Director	1/1/01
Roy A. Whitfield	Director/Founder	1/1/91

View All Key Executives

Brian W. Metcalf, Ph.D., age 62, has served as Executive Vice President and Chief Drug Discovery Scientist since February 2002. From March 2000 to February 2002, Dr. Metcalf served as Senior Vice President and Chief Scientific Officer of Kosan Biosciences Incorporated. From December 1983 to March 2000, Dr. Metcalf held a number of executive management positions with SmithKline Beecham, most recently as Senior Vice President, Discovery Chemistry... View Full Profile

Brian W. Metcalf, Ph.D.

John A. Keller, Ph.D., age 43, has served as Executive Vice President and Chief Business Officer since September 2003. From January 2001 to September 2003, Dr. Keller served as Vice President, Business Development at GlaxoSmithKline. From February 1987 to January 2001, Dr. Keller held a range of positions at SmithKline Beckman and SmithKline Beecham, in areas encompassing discovery research, project management, R&D strategy, alliance management... View Full Profile

John A. Keller, Ph.D.

Patricia A. Schreck, age 54, joined Incyte as Executive Vice President and General Counsel in December 2003. Prior to joining Incyte, Ms. Schreck was Chief Patent Counsel at Elan Drug Delivery, Inc. Previously, she served as General Counsel for Genomics Collaborative, Inc. and diaDexus, Inc. (a SmithKline Beecham and Incyte joint venture). From 1992 through 1998, Ms. Schreck held a variety of senior patent and corporate legal positions at... View Full Profile

Patricia A. Schreck

Richard U. De Schutter has been Chairman of the Company's Board of Directors since 2004. He was Chairman and Chief Executive Officer of DuPont Pharmaceuticals Company, a drug manufacturer formerly based in Wilmington, Delaware, from July 2000 to October 2001. He served as Chief Administrative Officer of Pharmacia Corporation between April 2000 and July 2000. From January 1999 through March 2000, Mr. De Schutter served as Vice Chairman and Chief... View Full Profile

Richard U. De Schutter

Paul A. Brooke has been Chairman of the Board of Directors of Alsius Corporation, a medical device company, since June 2007, and was the Chairman and Chief Executive Officer of a predecessor company from 2005 to June 2007. Mr. Brooke has been the Managing Member of PMSV Holdings, LLC, a private investment firm, since 1993. He has also served as a Senior Advisor to Morgan Stanley & Co. Incorporated since April 2000, and was a Venture Partner at... View Full Profile

Paul A. Brooke

Paul A. Friedman, M.D. joined the Company as the Chief Executive Officer in November 2001 and has been President of the Company since May 2004. From 1998 until October 2001, Dr. Friedman served as President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of DuPont Pharmaceuticals Company (formerly The DuPont Merck Pharmaceutical Company), from 1994 to 1998 he served as President of Research and Development of The DuPont... View Full Profile

Paul A. Friedman, M.D.

Roy A. Whitfield co-founded the Company and served as Chairman of the Board from November 2001 until June 2003. Mr. Whitfield served as Chief Executive Officer of the Company between June 1993 and November 2001, as President of the Company from June 1991 until January 1997, and as Treasurer of the Company between April 1991 and October 1995. From 1984 to 1989, he held senior operating and business development positions with Technicon Instruments... View Full Profile

Roy A. Whitfield

Julian C. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker's firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker's career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the... View Full Profile

Julian C. Baker

John F. Niblack, Ph.D. retired from Pfizer Inc. in September 2002, where he had served as its Vice Chairman since May 1999, and as a director since June 1997. From June 2000 to July 2002, he also served as President of Pfizer Global Research and Development. Dr. Niblack was Executive Vice President of Pfizer from 1993 to May 1999 and was responsible for Pfizer's Global Research and Development Division and Pharmaceutical Licensing and... View Full Profile

Dr. John F. Niblack, Ph.D.

Matthew W. Emmens has been the Chief Executive Officer, Chairman of the Management Committee and a member of the Board of Directors of Shire plc, a global specialty pharmaceuticals company, since 2003. Effective June 2008, Mr. Emmens will become Non-Executive Chairman of Shire, at which time he will step down as Chief Executive Officer of Shire. From 2001 to 2003, Mr. Emmens served as president of Merck KGaA's global prescription pharmaceuticals... View Full Profile

Matthew W. Emmens

David C. Hastings, age 46, has served as Executive Vice President and Chief Financial Officer since October 2003. From February 2000 to September 2003, Mr. Hastings served as Vice President, Chief Financial Officer, and Treasurer of ArQule, Inc. Prior to his employment with ArQule, Mr. Hastings was Vice President and Corporate Controller at Genzyme, Inc., where he was responsible for the management of the finance department. Prior to his... View Full Profile

David C. Hastings, CPA

Barry M. Ariko has been President and Chief Executive Officer of Mirapoint, Inc. since November 2003, and has been its Chairman of the Board since December 2003. From April 2001 until September 2001, Mr. Ariko was Senior Vice President of Peregrine Systems, Inc., an infrastructure management software company, and from April 2001 until June 2002 was a member of its Board of Directors. From March 2000 until the acquisition of Extricity, Inc. by... View Full Profile

Barry M. Ariko

On June 1, 2005, the Company's Board of Directors appointed Laurent Chardonnet, age 40, as the Company's Vice President, Finance and Treasurer. Mr. Chardonnet joined the Company in February 2004 as Vice President of Financial Planning and Analysis, and was promoted to Vice President, Finance in April 2005. From 2000 to 2004, Mr. Chardonnet served as Vice President, Finance of DrugAbuse Sciences, Inc., a privately held biotechnology company, and... View Full Profile

Laurent Chardonnet

Paula Swain, age 50, has served as Executive Vice President, Human Resources, of Incyte since August 2002 and joined the company as Senior Vice President of Human Resources in January 2002. Ms. Swain served as Senior Vice President of Human Resources at Bristol Meyers Squibb from October 2001 to January 2002, after they acquired DuPont Pharmaceuticals Company. From July 1998 to October 2001, Ms. Swain was Senior Vice President of Human Resources... View Full Profile

Paula J. Swain

Top Competitors: INCY

View Detailed Competitors Chart

Insider Trends: INCY
Sentiment for INCY is POSITIVE
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: INCY

Date	Name	Shares	Transaction Type	Market Value
07/31/08	BAKER BROS CAPITAL GP L L C	1,539	Purchase	$13,851.00
07/31/08	14159 CAPITAL GP L L C	27,724	Purchase	$249,516.00
07/31/08	BAKER TISCH CAPITAL GP L L C	4,997	Purchase	$44,973.00

View All Insider Activity

Ownership Breakdown : INCY

Large Block Holder Type	Number
Institutions	161.00
Mutual Fund	242.00
Other Major	8.00

Full Details

Indices : INCY

Symbol	Name	Last Trade	Change
$RUT.X	Russell 2000 Index	—	——%

View all Indices that include INCY

Short Interest Volume: INCY

Data as of 7/28/08

Current Short Interest Shares	18.14 M
Current Short Interest Ratio	20.20
Float	83.57 M

Short Interest as % of Float	21.70
Average Daily Volume	1.18 M
Outstanding Shares	95.49 M

Full Details

SEC Filings: INCY

Accepted Date	Description
08/07/2008	SEC Filing: >= 5% Acquisition
08/06/2008	SEC Filing: Current Event
08/05/2008	SEC Filing: Insider Buy/Sell

View all SEC Filings

Get Quote Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

INCYTE CORP

INCY

Stock price

9.54 -0.25 -2.55%

as of 04:00 PM EDT on 08/21/2008 in USD (NASDAQ Delay: 15 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell
- Strong Sell
- Add to Portfolio
- Add to Alerts

Quote Search Search the Web Search

More on Money & Finance
- Money
- Earnings
- Tech News
- Stock Screener
- Walletpop
- Banking
- Checking Account
- Savings Account
- Credit Cards
- Credit Reports
- Identity Theft
- Debt Management
- Loans
- Auto Loan
- Personal Loans
- Mortgages
- Refinancing
- Taxes
- Tax Filing
- Tax Advice
- Tax Basics
- Tax Forms
- Audit
- Tax Credit
- Tax Deduction
- AMT
- Small Business
- BloggingStocks
- BloggingBuyouts
- Luxist
- TUAW
- DJIA
- Dow Jones Industrial Average
More Stock Research
Notices and Terms: Confirm all data with your broker before trading.

Quote data provided by Interactive Data. Real-Time prices provided by BATS. Historical prices provided by Prophet. Company Profile provided by Hoovers. Executive data and Industry/Sector information provided by Morningstar Inc. Earnings, Ownership, Financial Statement, Insider Trading, Conference Call schedules and SEC Filing information provided by Thomson Financial.

© 2008 AOL LLC. All Rights Reserved.

AOL@Money © 2008 AOL LLC. All Rights Reserved.

Live Updates:

Ticker

Dynamic view of the market

INCYTE CORP

INCY

Stock price

Extended Hours

Analyst Consensus

INCYTE CORP Profile

Key Executives: INCY

Top Competitors: INCY

Insider Trends: INCY

Insider Transactions: INCY

Ownership Breakdown : INCY

Indices : INCY

Short Interest Volume: INCY

SEC Filings: INCY

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials